Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06WTZ
|
|||
| Former ID |
DAP000551
|
|||
| Drug Name |
Lovastatin
|
|||
| Synonyms |
lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypercholesterolaemia [ICD-11: 5C80.0] | Approved | [1], [2] | |
| Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 3 | [3] | ||
| Therapeutic Class |
Anticholesteremic Agents
|
|||
| Company |
Atos Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H36O5
|
|||
| Canonical SMILES |
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
|
|||
| InChI |
1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
|
|||
| InChIKey |
PCZOHLXUXFIOCF-BXMDZJJMSA-N
|
|||
| CAS Number |
CAS 75330-75-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9285, 496591, 623233, 855905, 7734777, 7847425, 7885508, 7979813, 8150103, 8182985, 10321765, 10852021, 11336207, 11361446, 11372945, 11462418, 11466544, 11467664, 11486128, 11491688, 11528634, 12012664, 12146073, 14806053, 14879393, 17389841, 22395934, 24896706, 25622285, 26612569, 26680612, 26697338, 26751557, 26759065, 34717349, 46391668, 46508223, 47515402, 47589078, 47662390, 47662391, 47662392, 47736583, 47959858, 47959859, 48035229, 48185079, 48334593, 48413948, 48416187
|
|||
| ChEBI ID |
CHEBI:40303
|
|||
| ADReCS Drug ID | BADD_D01325 | |||
| SuperDrug ATC ID |
C10AA02
|
|||
| SuperDrug CAS ID |
cas=075330755
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides cellulosilyticus DSM 14838
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides cellulosilyticus DSM 14838 (log2FC = -1.041; p = 0.015). | |||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -1.076; p = 0.034). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.679; p = 0.002). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.789; p = 0.005). | |||
|
Studied Microbe: Bacteroides fragilis NCTC 9343
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides fragilis NCTC 9343 (log2FC = -0.884; p = 0.006). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.666; p = 0.01). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.71; p = 0.002). | |||
|
Studied Microbe: Bacteroides intestinalis DSM 17393
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides intestinalis DSM 17393 (log2FC = -0.444; p = 0.025). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.419; p = 0.008). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.632; p = 0.016). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.94; p = 0.002). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -1.244; p = 0.002). | |||
|
Studied Microbe: Bacteroides WH2
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides WH2 (log2FC = -0.486; p = 0.024). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.5; p = 0.005). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Odoribacter splanchnicus (log2FC = -0.782; p = 0.004). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.716; p = 0.013). | |||
|
Studied Microbe: Parabacteroides johnsonii DSM 18315
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Parabacteroides johnsonii DSM 18315 (log2FC = -0.931; p = 0.005). | |||
|
Studied Microbe: Parabacteroides merdae ATCC 43184
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Parabacteroides merdae ATCC 43184 (log2FC = -0.633; p = 0.048). | |||
|
Studied Microbe: Pretovella copri DSM 18205
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Pretovella copri DSM 18205 (log2FC = -0.365; p = 0.035). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium adolescentis ATCC 15703
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bifidobacterium adolescentis ATCC 15703 (log2FC = -1.11; p = 0.004). | |||
|
Studied Microbe: Bifidobacterium breve DSM 20213
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Bifidobacterium breve DSM 20213 (log2FC = -0.685; p = 0.005). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella lenta ATCC 25559
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Eggerthella lenta ATCC 25559 (log2FC = -0.4; p = 0.006). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Eubacterium biforme DSM 3989
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Eubacterium biforme DSM 3989 (log2FC = -0.61; p = 0.005). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium asparagiforme DSM 15981
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Clostridium asparagiforme DSM 15981 (log2FC = -0.642; p = 0.006). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Clostridium sp. (log2FC = -0.856; p = 0.014). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Victivallales | ||||
|
Studied Microbe: Victivallis vadensis ATCC BAA-548
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Lovastatin can be metabolized by Victivallis vadensis ATCC BAA-548 (log2FC = -0.462; p = 0.027). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [5], [6], [7], [8], [9] | |||
| Metabolic Reaction | Hydroxylation and ring fission | |||
| Resulting Metabolite | 2-hydroxy lovastatic acid | |||
| Metabolic Effect | Increase activity | |||
| Description | Lovastatin can be metabolized to 2-hydroxy lovastatic acid by gut microbiota through hydroxylation and ring fission, which results in the increase of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Inhibitor | [10] |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Mevalonate pathway | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| AMPK signaling pathway | ||||
| Bile secretion | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| TSH Signaling Pathway | ||||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| WikiPathways | Statin Pathway | |||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
| Activation of Gene Expression by SREBP (SREBF) | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2739). | |||
| REF 2 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 3 | Clinical pipeline report, company report or official report of CardioPharma Wilmington. | |||
| REF 4 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 5 | Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev. 2018 Aug;50(3):357-368. | |||
| REF 6 | Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998 Aug;64(2):177-82. | |||
| REF 7 | Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 2014 Sep;42(9):1508-13. | |||
| REF 8 | Gut Microbiota-Mediated Drug-Antibiotic Interactions. Drug Metab Dispos. 2015 Oct;43(10):1581-9. | |||
| REF 9 | A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:5703-6. | |||
| REF 10 | Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.